These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 2087089

  • 1. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A, Karádi I, Köszegi G, Pados G, Németh-Csóka M, Pichler M, Romics L.
    Klin Wochenschr; 1990; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract] [Full Text] [Related]

  • 2. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A, Bonaiuto M, Lanzafame F, Mileto A, Pernice F, Cinquegrani M, Mazza G, Micali G, Pangallo A, Fodale P.
    Clin Ter; 1988 Mar 15; 124(5):373-81. PubMed ID: 2974348
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M, Eber B, Silberbauer K, Breier C, Stühlinger W, Schmidt P, Gaul G, Klein W.
    Acta Med Austriaca; 1992 Mar 15; 19(5):140-4. PubMed ID: 1298143
    [Abstract] [Full Text] [Related]

  • 4. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A, Sommariva D, Tirrito M, Bonfiglioli D, Pini C, Scandiani L, Orlandi S, Fasoli A.
    Clin Ter; 1987 Jul 15; 122(1):17-23. PubMed ID: 2973892
    [No Abstract] [Full Text] [Related]

  • 5. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H, Weidmann P, Fragiacomo C, Noseda G, Bachmann C.
    Schweiz Med Wochenschr; 1985 Jun 29; 115(26):907-11. PubMed ID: 3927481
    [Abstract] [Full Text] [Related]

  • 6. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul 29; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 7. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
    Muacević-Kataneca D, Bradamante V, Reinec Z, Sucić M, Poljicanin T, Busljeta I, Metelko Z.
    Arzneimittelforschung; 2005 Jul 29; 55(5):271-5. PubMed ID: 15960426
    [Abstract] [Full Text] [Related]

  • 8. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias.
    Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald H.
    Surgery; 1990 Oct 29; 108(4):601-10; discussion 610-1. PubMed ID: 2120785
    [Abstract] [Full Text] [Related]

  • 9. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Oct 29; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 10. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L, Németh Csóka M, Szám I, Pados G, Karádi I, Köszegi G, Kusztos R.
    Orv Hetil; 1986 Oct 05; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract] [Full Text] [Related]

  • 11. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ, O'Bryan-Tear CG.
    Postgrad Med J; 1996 Dec 05; 72(854):739-43. PubMed ID: 9015467
    [Abstract] [Full Text] [Related]

  • 12. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 13. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Apr 22; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 14. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 15. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia.
    Avogaro P, Bittolo Bon G, Cazzolato G, Soldan S, Bufalino L.
    Drugs Exp Clin Res; 1989 Dec 06; 15(6-7):325-33. PubMed ID: 2686956
    [Abstract] [Full Text] [Related]

  • 16. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M, Sailer S, Irsigler H, Klein W, Patsch JR.
    Wien Med Wochenschr; 1995 Dec 06; 145(21):577-83. PubMed ID: 8560901
    [Abstract] [Full Text] [Related]

  • 17. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A, Ljachnicky N.
    Schweiz Rundsch Med Prax; 1988 Jul 05; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract] [Full Text] [Related]

  • 18. [Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia].
    Kiseleva NG.
    Klin Med (Mosk); 1994 Jul 05; 72(3):20-4. PubMed ID: 7990345
    [Abstract] [Full Text] [Related]

  • 19. Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
    Hanefeld M, Lang PD, Fischer S, Leonhardt W, Bergmann S, Jaross W.
    Arzneimittelforschung; 1988 Dec 05; 38(12):1835-7. PubMed ID: 3245857
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
    Sommariva D, Tirrito M, Bonfiglioli D, Pogliaghi I, Branchi A, Cabrini E.
    Int J Clin Pharmacol Res; 1986 Dec 05; 6(3):249-53. PubMed ID: 3744628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.